Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ResMed Inc. (RMD) vs SkyWest Inc (SKYW) Price & Performance

ResMed Inc.Trade
SkyWest IncTrade

Price performance (Past 24H)

Key statistics

ResMed Inc. vs SkyWest Inc — how do they compare? ResMed Inc. trades at $230.05 (market cap $31.89B), while SkyWest Inc trades at $96.52 (market cap $3.75B). The key difference: ResMed Inc. is far larger — about 8.5× SkyWest Inc's market cap, and ResMed Inc. pays a 1.16% dividend while SkyWest Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and SkyWest Inc for 8 Days on average.

RMDSKYW
Market Cap
$31.89B$3.75B
Volume
618,314196,324
Sector
HealthIndustrials
52-Week High
$275.96$115.94
52-Week Low
$182.82$78.40
Typical Hold Time
51 Days8 Days
Enterprise Value
$31.24B$5.54B
Dividend Yield
1.16%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ResMed Inc.

ResMed (RMD) trades at $226.73, up 0.33% today, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15 billion in 2025, with a net income margin of 26.94%, while cash flow from operations reached $1.75 billion. Recent news highlights an upcoming Q1 2027 earnings report and management's focus on 12%-14% EPS growth driven by demand in sleep therapy.

The outlook for RMD is positive, supported by robust fundamentals and analyst consensus, though risks include competitive pressures and ongoing legal investigations. Upside potential exists with a consensus price target of $242.70, representing a 7% increase from current levels, but investors should monitor execution against growth targets and market share dynamics.

SkyWest Inc

SkyWest (SKYW) trades at $96.73, showing minimal daily movement (+0.09%) amid mixed technical signals. The stock presents attractive valuation metrics with a P/E of 9.6 and P/S of 0.94, supported by solid profitability including 9.78% net income margin and 15.34% ROE. Recent earnings performance has been inconsistent with two misses and one beat in the last three quarters, while analyst sentiment remains positive with 59% buy ratings and a $112 consensus target representing 16% upside potential.

The outlook for SKYW balances strong fundamentals against near-term headwinds. Fleet modernization and expanded flying agreements provide growth catalysts, but cost pressures and mixed quarterly results create uncertainty. With technical indicators showing bearish momentum and executives reducing positions, investors should weigh the compelling valuation against execution risks in a competitive airline industry environment.

Returns comparison

Trailing returns across standard periods

About ResMed Inc.

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Read more on RMD →

About SkyWest Inc

SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.

Read more on SKYW →